Compare ADAM & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADAM | SLBT |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.0M | 644.9M |
| IPO Year | 2003 | 2025 |
| Metric | ADAM | SLBT |
|---|---|---|
| Price | $6.01 | $1.21 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 45.0K |
| Earning Date | 10-28-2026 | 10-26-2026 |
| Dividend Yield | ★ 18.35% | N/A |
| EPS Growth | ★ 196.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.59 | N/A |
| P/E Ratio | $7.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.55 | $1.02 |
| 52 Week High | $10.36 | $6.25 |
| Indicator | ADAM | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 19.31 | 33.19 |
| Support Level | N/A | $1.02 |
| Resistance Level | $9.36 | $1.75 |
| Average True Range (ATR) | 0.31 | 0.16 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 5.00 | 28.77 |
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.